Plusonermin
Plusonermin is a recombinant form of human insulin-like growth factor 1 (IGF-1), a protein that plays a crucial role in growth and development. It is primarily used in research settings to study its effects on various physiological processes and potential therapeutic applications.
Mechanism of Action[edit | edit source]
Plusonermin functions by mimicking the action of natural IGF-1, which binds to the insulin-like growth factor 1 receptor (IGF-1R) on the surface of cells. This binding activates intracellular signaling pathways, including the PI3K/AKT/mTOR pathway and the MAPK/ERK pathway, which are involved in cell growth, proliferation, and survival.
Therapeutic Applications[edit | edit source]
Research into Plusonermin has explored its potential in treating conditions such as growth hormone insensitivity, muscle wasting, and neurodegenerative diseases. Its ability to promote cell growth and survival makes it a candidate for therapies aimed at tissue regeneration and repair.
Growth Hormone Insensitivity[edit | edit source]
In patients with growth hormone insensitivity, Plusonermin may help stimulate growth by providing an alternative pathway to promote growth and development, bypassing the need for growth hormone.
Muscle Wasting[edit | edit source]
Plusonermin has been studied for its potential to counteract muscle wasting in conditions such as cachexia and sarcopenia. By promoting muscle cell growth and inhibiting apoptosis, it may help maintain muscle mass and function.
Neurodegenerative Diseases[edit | edit source]
The neuroprotective effects of Plusonermin are being investigated in diseases like Alzheimer's disease and Parkinson's disease. Its ability to support neuronal survival and function could offer therapeutic benefits in slowing disease progression.
Safety and Side Effects[edit | edit source]
As with any therapeutic agent, the safety profile of Plusonermin is a critical consideration. Potential side effects may include hypoglycemia, due to its insulin-like activity, and other effects related to excessive cell proliferation.
Research and Development[edit | edit source]
Ongoing research is focused on optimizing the delivery and efficacy of Plusonermin, as well as understanding its long-term effects and safety in various patient populations.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
